John Alam’s Post

From sci-fi to reality → 👁️ transplants to restore vision Advanced Research Projects Agency for Health (ARPA-H) awarded $47 million to the project Human Eye-allotransplantation Innovation Advancement (THEIA), led in part by USC Roski Eye Institute, to supercharge bringing eye transplantation forward to clinical trial.

QurAlis Presents! QurAlis' associate director of clinical operations Samantha Rubino presented a poster on our Phase 1 clinical trial of QRL-101 at the 3rd Australia and New Zealand #MND Research Symposium. QRL-101 is a first-in-class selective #Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in #ALS. Kv7.2 is a mis-spliced protein in people with sporadic ALS. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

Day 2: Another two poster pesentations at ASCEPT, APFP & APSA Joint Congress 2024: Neuroprotective effect of astaxanthin nanoemulsion in middle cerebral artery occlusion stroke model • Poster P450 | 10:30 AM - 11:10 AM, Dec 3 • Neuropharmacology (ASCEPT) Efficacy and Safety of Immunotherapies for Alzheimer's Disease: A Network Meta-Analysis • Poster P449 | 1:15 PM - 2:10 PM, Dec 3 • Neuropharmacology (ASCEPT) #ASCEPT #APFP #APSA

Fabulous news to share! Clinical outcomes from the TED (thyroid eye disease) research show a 71% reduction in proptosis > 2mm (active cohort), with a mean improvement of 2.3 mm by Hertels and 2.8 mm by volumetric orbital imaging. This is a significant improvement as compared to the 42% responder rate for the chronic cohort. It's great to see a focus on a neglected disease, and this research will help create new options for our TED tool chest with translational applications in medical fields. #TEDresearch #thyroideyedisease #clinicaloutcomes #medicalresearch

Cassava Sciences announced that topline results from the Phase 3 ReThink-ALZ study of #simufilam for mild-to-moderate Alzheimer's disease (AD) did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints. https://lnkd.in/dzkxesCx PS: Simufilam is a small molecule that was administered orally with the aim of targeting an altered form of the protein FLNA (Filamin A). FLNA is an actin-binding protein that links actin filaments to membrane glycoproteins, participating in cytoskeletal remodeling. Altered filamin A enables beta-amyloid-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease. Simufilam was intended to reduce the buildup of toxic proteins, such as beta-amyloid and tau, linked to brain cell loss and cognitive dysfunction.

Momentum in #Alzheimer's diagnostics continues with a new study from JAMA showing the Alzheimer's Drug Discovery Foundation's funded PrecivityAD #bloodtest from C2N Diagnostics was more accurate in diagnosing the disease than CT scans and cognitive testing. The study, which was presented at the Alzheimer's Association®conferce today, showed the blood test was 90% accurate in identifying whether patients with memory problems had Alzheimer's. Advances in #biomarkers are emblematic of the new era of Alzheimer's research where novel biomarkers, such as blood tests, offer accessible diagnostic tools to enable early detection and diagnosis as well as help accelerate clinical research. Only with an early and accurate way to diagnose the disease, can the field move closer to a #precisionmedicine approach where clinicians can personalize treatments based on each patients' individual biomarker profile. The C2N test is part of the ADDF's larger robust biomarker portfolio - led by the Diagnostics Accelerator - that encompasses blood tests, retinal scans and digital tools, which will eventually work in tandem to provide patients with simple and accurate diagnoses in real-time. #AAIC24

We’re thrilled to share more encouraging updates from Neurizon Therapeutics’ Open-Label Extension (OLE) Study in patients with ALS. The latest data reveals that treatment with NUZ-001 remains well-tolerated and continues to demonstrate promising results in slowing disease progression and extending life expectancy compared to untreated matched controls. Our commitment to advancing this innovative therapy remains stronger than ever as we work to bring hope and new possibilities to the ALS community.   📖 Read the full press release here: https://lnkd.in/e-e2ydzY #ALS #NeurodegenerativeDiseases #NeurizonTherapeutics #HorizonOfHope

INSIDE LOOK 👀 Read the latest research from the upcoming issue (November 7): Despite the role of bronchoscopy and pulmonology societal guidelines for staging, qualitative research finds that pulmonologists lack the necessary resources and multidisciplinary infrastructure likely required to efficiently accomplish biomarker testing. https://hubs.la/Q02WGx1n0 #MedEd #JournalCHEST

This #NationalScienceWeek, Australia’s annual celebration of science and technology, we are featuring some of the country's most innovative Parkinson's researchers and their work to slow, stop and cure Parkinson's disease. In this chat with Dr. Fazel Shabanpoor from The Florey, we hear about his research into antisense oligonucleotides, which offer a new therapeutic strategy in Parkinson’s disease because they can be readily targeted to genes linked to PD development or progression. This means they can treat the underlying pathology of PD, not just symptoms, and profoundly alter its progression and impact on patients. https://buff.ly/4dFnxja #SlowStopCureParkinsons #ShakeItUpAustralia #SolvingTheParkinsonsPuzzle